JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target
Critical Insights From OptimizeRx Analyst Ratings: What You Need To Know
JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $16 Price Target
OptimizeRx Analyst Ratings
OptimizeRx Analyst Ratings
Stifel Nicolaus Reaffirms Their Buy Rating on OptimizeRx (OPRX)
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), PepGen Inc. (PEPG) and RegenXBio (RGNX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: OptimizeRx (OPRX), Immunocore Holdings (IMCR) and Acadia Healthcare (ACHC)
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and OptimizeRx (OPRX)
Lake Street Sticks to Their Buy Rating for OptimizeRx (OPRX)
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), OptimizeRx (OPRX) and AbbVie (ABBV)
Analysts Offer Insights on Healthcare Companies: OptimizeRx (OPRX), Alvotech (ALVO) and Pacific Biosciences (PACB)
J.P. Morgan Securities: Reiterated the OptimizeRX (OPRX.US) rating and adjusted from superior to superior market rating, with a target price of $15.00.
OptimizeRx Analyst Ratings
JMP Securities Reiterates Market Outperform on OptimizeRx, Maintains $15 Price Target
Analysts Are Bullish on These Healthcare Stocks: OptimizeRx (OPRX), Day One Biopharmaceuticals (DAWN)
Analysts Are Bullish on Top Healthcare Stocks: OptimizeRx (OPRX), Ocular Therapeutix (OCUL)
OptimizeRx Analyst Ratings
JMP Securities Initiates Coverage On OptimizeRx With Market Outperform Rating, Announces Price Target of $15
OptimizeRx Analyst Ratings